Systemic Corticosteroids Avoidance Study in Severe Asthma Patients
Status:
Terminated
Trial end date:
2020-02-06
Target enrollment:
Participant gender:
Summary
The overall purpose of this study was to determine the efficacy of fevipiprant (150 mg and
450 mg once daily), compared with placebo, as add-on to standard-of-care asthma therapy, in
terms of avoidance of corticosteroid use over 52 weeks.